Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
BioConferenceLive

Blood Collection Device Minimizes Cellular DNA Release

By BiotechDaily International staff writers
Posted on 27 Aug 2013
Image: Cell-free DNA BCT tube (Photo courtesy of Streck, Inc.).
Image: Cell-free DNA BCT tube (Photo courtesy of Streck, Inc.).
Cell-free DNA (cfDNA) circulating in blood is currently used for noninvasive diagnostic and prognostic tests and minimizing background DNA is vital for detection of low abundance cfDNA.

A newly introduced blood collection device could reduce background levels of genomic DNA (gDNA) in plasma compared to standard tubes, when subjected to conditions that may occur during sample storage and shipping.

Scientists working for a commercial manufacturer took blood samples from healthy donors into tri-potassium ethylenediaminetetraacetic acid (K3EDTA) tubes and Cell-Free DNA BCT (BCT), which is a new collection device that contains a novel chemical cocktail. Samples were shaken or left unshaken to simulate shipping. In a shipping study, samples were shipped or not shipped. To assess temperature variations, samples were incubated at 6 °C, 22 °C, and 37 °C. In all cases, plasma was harvested by centrifugation and total plasma DNA (pDNA) assayed by quantitative real-time polymerase chain reaction (qPCR). The QIAamp Circulating Nucleic Acid Kit (Qiagen; Santa Clarita, CA, USA) was used for the extraction of pDNA.

The BCT tubes are manufactured by Streck, Inc., (Omaha, NE, USA) while the K3EDTA tubes were the BD Vacutainer, (Becton Dickinson; Franklin Lakes, NJ, USA). Shaking of blood drawn into K3EDTA tubes showed a significant increase in pDNA over 24 hours whereas no change was seen in Cell-Free DNA BCT tubes. Blood incubated at 6 °C, 22 °C, and 37 °C showed significant increases in pDNA isolated from K3EDTA tubes, while pDNA levels from Cell-Free DNA BCT remained stable over 14 days.

The novel stabilizing chemical cocktail prevents the release of gDNA into plasma post phlebotomy up to 14 days, avoiding labor-intensive requirements. Using this blood collection device, ex vivo storage at room temperature becomes possible, allowing flexibility for offsite blood drawn to be sent to centralized laboratories for downstream analysis of the cfDNA without preliminary centrifugations or cryopreservation.

The authors concluded that Cell-Free DNA BCT tubes prevent increases in background gDNA levels caused by temperature fluctuations or agitation that can occur during blood sample storage, shipping and processing. This novel blood-collection tube provides a method for obtaining high quality stabilized samples for rare DNA target detection and determining accurate cfDNA concentrations. The study was published on July 12, 2013, in the Journal of Clinical Laboratory Analysis.

Related Links:

Qiagen
Streck, Inc.
Becton Dickinson



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Scanning electron micrograph of cultured human neuron from induced pluripotent stem cell (Photo courtesy of the University of California, San Diego).

Induced Stem Cells Show Genetic Abnormalities Not Found in Embryonic Stem Cells

All stem cells are not created equal: genomic evaluation revealed that the genome of stem cells generated from adult cells (induced pluripotent stem cells or iPS cells) differed considerably from that... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.